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Abstract
Survival of hepatitis A virus (HAV) and hepatitis E virus (HEV) in soil samples spiked with respective viruses was analysed using real-time
PCR. Virus-spiked soil samples were incubated at environmental temperature (ET) and 37C and processed weekly. Both HAV and
HEV were less stable at ﬂuctuating ET than at 37C. Of the 403 soil samples collected in the vicinity of Mutha river, India, 19.1% and
4.9% were found to be contaminated with HAV and HEV, respectively.
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Abstract
We report the emergence of carbapenem-resistant Enterobacteriaceae in Austria. Over a 10-year period, carbapenem-resistant Entero-
bacteriaceae isolates were obtained from 13 hospitalized patients, with the ﬁrst isolation in the year 2005 and a remarkable increase in
the number of involved patients in 2010. Carbapenem-resistant Enterobacteriaceae comprise eight Klebsiella pneumoniae isolates, four Kle-
bsiella oxytoca isolates, and one Escherichia coli isolate. The detected carbapenemases were the metallo-b-lactamases New Delhi b-lac-
tamase, VIM and IMP, and the serin-b-lactamase Klebsiella pneumoniae carbapenemase.
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Abstract
In recent years there has been renewed interest in colistin for the treatment of infections by multidrug-resistant Gram-negative bacte-
ria, causing concern that increasing use may be accompanied by the emergence of resistance. This is a retrospective cohort study of
colonization and infection by colistin-resistant (CR) gram-negative bacteria in critically ill patients. Colonization data were based on sur-
veillance culture results. Among 150 patients, 78 (52%) were colonized by CR Gram-negative bacteria. Among them, 30 (20%) were
colonized by Klebsiella pneumoniae isolates and 51 (34%) were colonized by intrinsically resistant to colistin (CIR) enterobacteriaceae.
Seven cases of infection were caused by CR K. pneumoniae and 12 cases by CIR strains. The main risk factor for colonization by CR
pathogens was colistin treatment.
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Abstract
In this study 45 isolates of Acinetobacter baumannii identiﬁed from patients in intensive care units of three different hospitals and from
pressure ulcers in home care patients in Palermo, Italy, during a 3-month period in 2010, were characterized. All isolates were resistant
to at least three classes of antibiotics, but susceptible to colistin and tygecycline. Forty isolates were non-susceptible to carbapenems.
Eighteen and two isolates, respectively, carried the blaOXA-23-like and the blaOXA-58-like genes. One strain carried the VIM-4 gene. Six
major rep-PCR subtype clusters were deﬁned, including isolates from different hospitals or home care patients. The sequence type/
pulsed ﬁeld gel electrophoresis group ST2/A included 33 isolates, and ST78/B the remaining 12. ST2 clone proved to be predominant,
but a frequent involvement of the ST78 clone was evident.
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Abstract
The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST)
has determined breakpoints for posaconazole for Candida spp. This Technical Note is based on the EUCAST posaconazole rationale
document (available on the EUCAST website: http://www.eucast.org). Species-speciﬁc breakpoints for C. albicans, C. parapsilosis and
C. tropicalis are S: MIC £0.06 mg/L, R: MIC >0.06 mg/L. There are insufﬁcient data to set breakpoints for C. glabrata and C. krusei as well
as non-species-related breakpoints. The breakpoints are based upon pharmacokinetic data, epidemiological cut-off values and clinical
experience. Breakpoints will be reviewed regularly.
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Abstract
The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing has determined
breakpoints for anidulafungin for Candida spp. This Technical Note is based on the EUCAST anidulafungin rationale document (available
at: http://www.eucast.org). Species-speciﬁc breakpoints for C. albicans are S £0.03 mg/L and R >0.03 mg/L and for C. glabrata, C. tropicalis
and C. krusei S £0.06 mg/L and R >0.06 mg/L. C. parapsilosis was not regarded a good target for anidulafungin. There are insufﬁcient data
to set breakpoints for other species. The breakpoints are based upon pharmacokinetic data, epidemiological cut-off values and clinical
experience. Breakpoints will be reviewed regularly.
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